HUE032816T2 - Amin só és annak kristályai - Google Patents

Amin só és annak kristályai Download PDF

Info

Publication number
HUE032816T2
HUE032816T2 HUE13832178A HUE13832178A HUE032816T2 HU E032816 T2 HUE032816 T2 HU E032816T2 HU E13832178 A HUE13832178 A HU E13832178A HU E13832178 A HUE13832178 A HU E13832178A HU E032816 T2 HUE032816 T2 HU E032816T2
Authority
HU
Hungary
Prior art keywords
compound
methyl
ethyl
thio
trifluoro
Prior art date
Application number
HUE13832178A
Other languages
English (en)
Inventor
Kousuke Tani
Akihiro Kinoshita
Keisuke Hanada
Yoshiyuki Aratani
Takahiro Nekado
Atsushi Shimabukuro
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of HUE032816T2 publication Critical patent/HUE032816T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Claims (5)

  1. Sssbad&isii igésyi^sRife
    1, VégyM«?: Akk képig·? p) aSeíysg
    ;âîÎ>I I ,v'V íí-k:>ηî>ira-i:Κ-ΪΛ; i<-gi:ozesn;H. J* : n'prexrsîU!, «s S:^»siguï:|ciéi i>--k<v4i:|.;;nk ?<:-*. vvgy <·;·:·;>< s:ep;i6kg«>; ax-k-y» od< IspykékéÎ rggíppaklAÁ vágy yikikk di?sxäMeyAAe kevsiSMí: é* 4-f»sjpá«áiamst«ööI^ assnsk krfetaíyék wgr a»n#k oliUxkUn;': fe|sgâï|iât.
  2. 2, Âx } igéav|H'Xi sisrinn sâ, îsssïîîI; krtsp?lÿ;s y?sgy ép?k?k ölkledyk??:!:?!: phok a vygyikgM k<-pk? f]| iagrcÄ-rnalj;?. am«! y ApA··;! sR3g?r2v.>Kv--5-k !kk4S}· ? y.8-inï1u«r.4-îs5<!n><i-4-:r!oi!· 1.,7-. (:ÀUx!X:î>dxlje-k!o|x\e?ki<4X}?xïj--l 2-u?:/í2-4-!;;irbO:í>xv.
  3. 3, Ay :!. sgéssvgiXX y»<»i«:?i sô* asxAk kdskÜys ysgy- sat»fe iplldtesto&amp;i». MÄtfe. A4··«, ssSKîîyç! képk·· ?;!) xepxx.v-xé.k 2k|pg ! ÇHxkFî-éoxo ->-f? ! PAS}· "AS AAAf! νον·4·Ηχ!κ(Α··4··:*·ϊΧ!' ? ,?-gÿkyiysïi^ïï- ï -ii}*5έΟΐΑΐΐ|>i 3*íí3Zö!^k8rha&amp;&amp;yv dsaaxXxixevix kevcAke. 4 A 4·. igépypgp?: ysengii Ά, sMyk koa-Piy;· vagy aspísj? :xk!->dcx?nn M?s?Adj?g sgpl .s :2.-4(¾^ {(4Rj!éj-.SxA»-'â-4Plé4g>?JAX?1:âPôr-44àd?yA^ pdl}?sd--I3~ í:ur!>v;.,í···>·k,:!;ix;í'va* dvsc-xseveí-íjiííí' .'-1;k?- K lS3RK3-a-'<\>3 ·ί< ! ??νΐ]ίκ;?·4··?44·χ>; ·4·:ίκ·.<.:···'!/3 ok-«dice - ! >3 je i.ki pppsö j }gp! jt ?ρ j -53-3323^4-kar b>:x· sav a,: ,-\;··. !.. Íyéuypon; xyePsis 3ϊη«!ν·|>!ι>&amp;ηβίη-4-ϋ·ηϊΡ?δ®Ρΐ.:2-|(3~;?ΑΕ.,5Ε:)-3Α^ί^·5··{{1ΙΪ^83··;73,8-·' l3fll?öí33Pd:?mÍ--4xAg3H,39k?sdiég4yijdkIg^ 34>ék áíavKtaíxeasísr kevvfakö, ap?3.k knMáiyss vagy ö?x>;sk okkxbA-xm k3xé$p?. 4, A.<·: t. Itépyppsk y-xenní; >3. an$d\ p!p?3dxa4 kmeiaruà 3:43-- p ! ssx1ί !4’ 4Α}-7..Α..Ν- tsiíltíiSr-4k-f !|c*iklsipissjsk< í ysies î ,3 xxsxík kmíéiva vagy aíspák eiktóéxSdA kkikápa. 7; A;·: k. igésyp>5?P sxsd?P?. mf arad y pspc*sdí;:.--4-:js?;<-í.as:-;>; A-i? ; R :(R>-2-îïao S :? 5 !; 43-333-- îï iîiUv-r---i--hi:i:'3xs'4 --!ï.xi!--! 3--:4Xs:i!dr3-X33kyAxi3 i cîs! ?i'o M3 -ί:*;'·':·Ι··4 -kgdxyydik ga síffiák dxía2:?:}c*;nsíi.-;:.h:Ck ps-iarxieM -dx-cíaxex 3143 p l/gA/M-oxo-g-p ! !/, 4S3? A.3;n!ls.:vr'-3hi<f :'<>>·i 4-srudk ? 3"A^4*l!#A';"'4j]e!k!opi4yj! 4x3443 3'ka23--Xk;u?K>x:3:u kvxcsvke. ássák k«stàiysÿ vagy .»öíjáfc nkkdeaud; kksr;k?a. g. ÀX.!:. U;3pp;xX *2<-r;»?s sé, íiSigíy fcépïe?: i Ü) ?Μ! jcgxamaák vvgyäk?«
    il <ü ;&amp;kö?Ígs5íáíSet Ihgyákkgalk ;> l.ORisgUi'ik iá· KgXC/.iSkâl és ,·······'·"' o-koakganKaO. iköííSjjfieiöS Vísgj; «A ákisahkíggs arányú kevmlksí. assisik kviskls yái vagy askJíxkxgis kkgág ál: sgptósggy íja. 9. A/. l'k: Igonypoxiok kaisndysks xxgxmíi I o so „N^xvdxíx,.'^ a < \ ' hnkklhHlk slaiay&amp;ft’selvsek vgigsak 2li ysaevgj fsgaíálhs a hövgikaaöfeÄ v.yy. 9,41. 12,91,. ! 1 96 c>. I y 99i: pók vvngvnddhídx ió:; sg®kk999>9Á 10 Az 1-1. sglayyssakak hâpsaiyik® sagrign: ksisîllÿ vagy g1Mo#xih kisÂ, amelynek vag kAsaîalka alakja, mxejyvek vsmxtk 20 massai legalább a kb\m.keæke.ek 8,9 1.9.?!. ! i .97: IÍ,2B #. i 2.88 · pív: kspigesalífefeíös g:·® ki maiban.
  4. 11, Ag ly#, jgégyjmtUök häimeiyiks saædms kmeály vagy ihkladexmis klalshk amelynek van knsgOlM alakié, am®Iy«9k wmixik M csiiesal legalább &amp;: k9v®feahks®k 9,11, 11,99, 19,19, 17,17 9* 19,99' peá sAmggMifíkkke les spakttmiksm
  5. 12, Cívégysaesrévaeís kgagkíaásjé, aSMjy haOsagaakém -aftaknaxa;· képtel (I) aha! rqxemmáb vegyi# et séjáf
    í ahol mkoellgunkail ebpmsgniál p-kíayílgöí&amp;csöt svyreseami. ás mkonflgeíáske. p4xndigarik»ál -.agy as mák misalleges ams'gv keverékei vagy imisak akaselss'smmx ikevsmkst ás, lysgendhmrseaxli: axpak knsiáiym. vagy áéhák eálodexlrm klm/elus· sepí®:KeeláI}e, 13, Λ, lil. i$és.yix>Ss skdinli denpexuAG MksssrdMsia kùgyhôlv&amp;s? iísmsssr idxedxiesdiban <'\ hsgws» :ïï>rsi:íc :c<·ί5<·k dkidpsbfcsíi. 14: A 13. dcíxpxni sæsHipi gy«gys:?eeessdí: koskpidldP !<deiH:x:d;d;';s köfv'holvög kösííAkdd dd/.k-^kvdäund·: édvSgy 3xigy%:sd ív;vascső ífdebuikeskgággk m<gA/>Ox<Scbv:n. kadél.fbee éSAdgy :.:*: : vbêê :*.üb:e ':. I S, ·\>· k ígAsgpösís íxenssd xsgyklss \ójS, smelvd S képlei (tf «?|xc,· estek ysgy ssssk PkddSISOmef k»s«éle*. és 4gk|xreidiaisek«xsk esssk 'tódéig«: wkgy mmfo Äfetaaf» -khúk}» -Mtomlte» hùgykéivâg·tólmÉ-kklés ddtóPtóébm étósgg kítóe-e:-b«e
HUE13832178A 2012-08-31 2013-08-30 Amin só és annak kristályai HUE032816T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012191080 2012-08-31

Publications (1)

Publication Number Publication Date
HUE032816T2 true HUE032816T2 (hu) 2017-11-28

Family

ID=50183705

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13832178A HUE032816T2 (hu) 2012-08-31 2013-08-30 Amin só és annak kristályai

Country Status (24)

Country Link
US (1) US9643940B2 (hu)
EP (1) EP2891651B1 (hu)
JP (1) JP6131956B2 (hu)
KR (1) KR102119619B1 (hu)
CN (1) CN104603117B (hu)
AU (1) AU2013309872B2 (hu)
BR (1) BR112015004459B1 (hu)
CA (1) CA2882732C (hu)
DK (1) DK2891651T3 (hu)
ES (1) ES2623788T3 (hu)
HK (1) HK1210168A1 (hu)
HU (1) HUE032816T2 (hu)
IL (1) IL237432B (hu)
MX (1) MX344385B (hu)
MY (1) MY177737A (hu)
NZ (1) NZ705340A (hu)
PH (1) PH12015500389A1 (hu)
PL (1) PL2891651T3 (hu)
PT (1) PT2891651T (hu)
RU (1) RU2658823C2 (hu)
SG (1) SG11201501451SA (hu)
TW (1) TWI597274B (hu)
WO (1) WO2014034902A1 (hu)
ZA (1) ZA201501374B (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543401A (ja) * 2019-08-04 2022-10-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド フルエンスルホンの製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (hu) 1970-06-10 1975-02-04
JPS5231404B1 (hu) 1971-04-28 1977-08-15
FR2204408A1 (en) * 1972-10-27 1974-05-24 Wirth Pierre Phenylbutazone salts - sol in water and well tolerated
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
JPS60197667A (ja) 1984-03-19 1985-10-07 Ono Pharmaceut Co Ltd ６―ケト―プロスタグランジン類似化合物及びその製造方法
DK1008588T3 (da) 1997-02-10 2003-07-28 Ono Pharmaceutical Co 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel
JPH11130678A (ja) 1997-08-27 1999-05-18 Kaken Pharmaceut Co Ltd 神経圧迫による神経障害改善剤
IL159996A0 (en) 2001-07-23 2004-06-20 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
WO2003074483A1 (fr) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
WO2004008411A1 (en) 2002-07-11 2004-01-22 Nokia Corporation Method and device for automatically changing a digital content on a mobile device according to sensor data
WO2004065365A1 (ja) 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. ８−アザプロスタグランジン誘導体およびその医薬用途
US20070167403A1 (en) 2003-04-03 2007-07-19 Yoshifumi Takenobu Remedy for spinal canal stenosis
EP1707208A4 (en) 2003-12-05 2010-03-17 Ono Pharmaceutical Co PROMOTER OF BLOOD FLOW IN THE TISSUES OF THE HORSE TAIL
WO2005061492A1 (ja) 2003-12-22 2005-07-07 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれらを有効成分とする薬剤
JP4888775B2 (ja) 2004-08-10 2012-02-29 小野薬品工業株式会社 Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
JP4893999B2 (ja) 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
TWI404529B (zh) * 2005-06-03 2013-08-11 Ono Pharmaceutical Co 神經再生及／或保護劑
JP5630264B2 (ja) 2008-06-06 2014-11-26 小野薬品工業株式会社 膀胱排尿筋収縮および尿道括約筋弛緩剤
CN102803239B (zh) * 2009-06-10 2015-04-15 小野药品工业株式会社 具有膀胱排尿肌收缩活性和尿道括约肌舒张活性的化合物

Also Published As

Publication number Publication date
KR102119619B1 (ko) 2020-06-05
HK1210168A1 (en) 2016-04-15
ES2623788T3 (es) 2017-07-12
EP2891651A4 (en) 2016-01-27
NZ705340A (en) 2018-06-29
IL237432B (en) 2019-05-30
US20150218114A1 (en) 2015-08-06
EP2891651B1 (en) 2017-03-08
DK2891651T3 (en) 2017-06-06
MX2015002209A (es) 2015-05-08
PH12015500389B1 (en) 2015-04-27
SG11201501451SA (en) 2015-04-29
US9643940B2 (en) 2017-05-09
CA2882732C (en) 2021-03-30
TWI597274B (zh) 2017-09-01
BR112015004459A2 (pt) 2017-07-04
AU2013309872A1 (en) 2015-03-19
PL2891651T3 (pl) 2017-08-31
ZA201501374B (en) 2016-03-30
CA2882732A1 (en) 2014-03-06
IL237432A0 (en) 2015-04-30
CN104603117A (zh) 2015-05-06
TW201414722A (zh) 2014-04-16
WO2014034902A1 (ja) 2014-03-06
KR20150047500A (ko) 2015-05-04
CN104603117B (zh) 2018-03-23
EP2891651A1 (en) 2015-07-08
PT2891651T (pt) 2017-05-08
PH12015500389A1 (en) 2015-04-27
JPWO2014034902A1 (ja) 2016-08-08
AU2013309872B2 (en) 2017-09-14
MY177737A (en) 2020-09-23
BR112015004459B1 (pt) 2020-06-30
JP6131956B2 (ja) 2017-05-24
RU2015111568A (ru) 2016-10-20
RU2658823C2 (ru) 2018-06-25
MX344385B (es) 2016-12-14

Similar Documents

Publication Publication Date Title
AU2017202625A1 (en) Targeted therapeutics
CN110256418A (zh) 1,3-噻唑-2-基取代的苯甲酰胺
US9150528B2 (en) Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
DK2891651T3 (en) AMINAL SALT AND CRYSTALL THEREOF
US20220396542A1 (en) Process for the preparation of ferric organic compounds
CN115485265A (zh) 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的共晶和盐